| 000 | 01831 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250517122810.0 | ||
| 264 | 0 | _c20180223 | |
| 008 | 201802s 0 0 eng d | ||
| 022 | _a1949-2553 | ||
| 024 | 7 |
_a10.18632/oncotarget.12859 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYang, Seung Ho | |
| 245 | 0 | 0 |
_aMetformin treatment reduces temozolomide resistance of glioblastoma cells. _h[electronic resource] |
| 260 |
_bOncotarget _cNov 2016 |
||
| 300 |
_a78787-78803 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aBrain Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Movement _xdrug effects |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aDacarbazine _xanalogs & derivatives |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aGene Expression Regulation, Neoplastic |
| 650 | 0 | 4 | _aGene Regulatory Networks |
| 650 | 0 | 4 |
_aGlioblastoma _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInhibitory Concentration 50 |
| 650 | 0 | 4 |
_aMetformin _xpharmacology |
| 650 | 0 | 4 | _aMice, SCID |
| 650 | 0 | 4 | _aNeoplasm Invasiveness |
| 650 | 0 | 4 |
_aSOXB1 Transcription Factors _xgenetics |
| 650 | 0 | 4 | _aTemozolomide |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTranscriptome |
| 650 | 0 | 4 |
_aTumor Burden _xdrug effects |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aLi, Shenglan | |
| 700 | 1 | _aLu, Guangrong | |
| 700 | 1 | _aXue, Haipeng | |
| 700 | 1 | _aKim, Dong H | |
| 700 | 1 | _aZhu, Jay-Jiguang | |
| 700 | 1 | _aLiu, Ying | |
| 773 | 0 |
_tOncotarget _gvol. 7 _gno. 48 _gp. 78787-78803 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.18632/oncotarget.12859 _zAvailable from publisher's website |
| 999 |
_c26558538 _d26558538 |
||